News from EAS 2025: results of the phase 2 GATEWAY trial

Frederick Raal

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Higher Lp(a) levels associated with recurrent ASCVD events, regardless of sex and race
Higher Lp(a) levels associated with recurrent ASCVD events, regardless of sex and race
EAS 2025
Higher Lp(a) levels associated with recurrent ASCVD events, regardless of sex and race
- Børge G. Nordestgaard, MD, DMSc
Long-term data of lomitapide in HoFH: 10-year observational data
Long-term data of lomitapide in HoFH: 10-year observational data
EAS 2025
Long-term data of lomitapide in HoFH: 10-year observational data
- Dirk Blom, PhD
Obicetrapib lowers LDL-c and other atherogenic lipids in patients at high risk of CV events
Obicetrapib lowers LDL-c and other atherogenic lipids in patients at high risk of CV events
EAS 2025
Obicetrapib lowers LDL-c and other atherogenic lipids in patients at high risk of CV events
- Stephen Nicholls, FRACP, FACC, FESC, FAHA